Status:
NOT_YET_RECRUITING
A Prospective Study: the Impact of Sleep Disturbances on Immunotherapy in Patients With Lung Cancer
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Lung Cancer (NSCLC)
Sleep Disorders, Circadian Rhythm
Eligibility:
All Genders
18-70 years
Brief Summary
In recent years, immunotherapy has made significant progress in the treatment of lung cancer, especially immune checkpoint inhibitors (such as PD-1/PD-L1 antibodies) against non-small cell lung cancer...
Detailed Description
Project title Association analysis between sleep disorders and tumor immunity in lung cancer: a prospective study Backgroundsleep disorders have been extensively studied in recent years and have been ...
Eligibility Criteria
Inclusion
- Diagnosis of non-small-cell lung cancer (stage II-IV) Age 18 and older Immune checkpoint inhibitor therapy (e.g., nivolumab, pembrolizumab, etc.) is planned.
- Be able to understand the study and provide informed consent
Exclusion
- Coexisting serious mental illness (e.g., major depression, anxiety, etc.) Recent chemotherapy or radiotherapy Other serious comorbidities (e.g., heart disease, liver and kidney insufficiency)
Key Trial Info
Start Date :
June 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2028
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT06953765
Start Date
June 1 2025
End Date
December 30 2028
Last Update
May 1 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.